Expanded repertoire of RASGRP2 variants responsible for platelet dysfunction and severe bleeding

Sarah K Westbury1,2, Matthias Canault3,4, Daniel Greene2,5,6

  • 1School of Clinical Sciences, University of Bristol, Bristol, United Kingdom.

Blood
|June 23, 2017
PubMed

Insights

Genetic variants in RASGRP2 cause CalDAG-GEFI deficiency, a platelet disorder with bleeding issues and impaired aggregation. This study defines the phenotype of this nonsyndromic, recessive platelet function disorder.

Area of Science:

  • Hematology
  • Genetics
  • Molecular Biology

Background:

  • Heritable platelet function disorders (PFDs) are genetically diverse and not well understood.
  • Previous studies linked pathogenic variants in RASGRP2 to bleeding and reduced platelet aggregation in a few families.

Purpose of the Study:

  • To define the clinical and laboratory phenotype of patients with pathogenic RASGRP2 variants.
  • To investigate the role of CalDAG-GEFI in platelet function and bleeding.

Main Methods:

  • High-throughput sequencing and phenotype data from 2042 cases with bleeding or platelet disorders were compared to 5422 controls.
  • Analysis of 11 novel, likely pathogenic, biallelic RASGRP2 variants.

Main Results:

  • Eleven new RASGRP2 variants were identified in cases, including high-impact and missense variants affecting Rap1 activation.
  • Patients exhibited mucocutaneous, surgical, and dental bleeding from childhood, with 78% requiring transfusions.
  • Platelet aggregation was reduced with ADP and epinephrine, showing variable defects with other agonists.

Conclusions:

  • Human CalDAG-GEFI deficiency is a nonsyndromic, recessive PFD.
  • It is characterized by moderate-to-severe bleeding and complex platelet aggregation defects.

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
4.1K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.4K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.4K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.6K